The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-15 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The Copenhagen physicists then started a campaign to re-award priority for element 71 to Welsbach and replace the name lutetium with cassiopeium, writing to Welsbach in 1923 of their intentions. This campaign encountered success in the physics literature, but in spite of strong German and Scandinavian support for cassiopeium, lutetium remained embedded in most of the chemical literature, with the International Commission on Atomic Weights in 1930 accepting that element 72 was hafnium but using lutetium for element 71. In 1949, it was decided by the International Union of Pure and Applied Chemistry to recommend the name lutetium, since cassiopeium by then was only used in German and sometimes Dutch, and it was a difficult name to adapt to other languages. It was nonetheless clarified that this was not intended as a statement on priority. Urbain's spelling lutecium was changed to lutetium, in order to derive the name from Latin Lutetia instead of French Lutèce. Pure lutetium metal was first produced in 1953.
24 September – Scientists report the successful return of samples from NASA's OSIRIS-REx mission to the asteroid 101955 Bennu. Shortly after the sample container was retrieved and transferred to an "airtight chamber at the Johnson Space Center in Houston, Texas", the lid on the container was opened. Scientists commented that they "found black dust and debris on the avionics deck of the OSIRIS-REx science canister" on the initial opening. Later study was planned. A news conference on the asteroid sample is scheduled for 11 October 2023. 25 September A study on Pangaea Ultima finds that the hypothetical supercontinent will make Earth uninhabitable to most life forms in 250 million years, due to extreme temperatures and radiation. Biologists report the discovery of a ninth species of pangolin, a mammal which is covered with large, protective keratin scales. 26 September – Work begins on the seventh and final primary mirror of the Giant Magellan Telescope, which is expected to provide quadruple the image resolution of previous observatories when completed.
The Ghana Prisons Service and the sub-division Borstal Institute for Juveniles administers incarceration. The new sustainable development goals adopted by the United Nations call for the international community to come together to promote the rule of law; support equal access to justice for all; reduce corruption; and develop effective, accountable, and transparent institutions at all levels. Ghana is used as a key narcotics industry transshipment point by traffickers, usually from South America and some from other African nations. In 2013, the UN chief of the Office on Drugs and Crime stated that "West Africa is completely weak in terms of border control and the big drug cartels from Colombia and Latin America have chosen Africa as a way to reach Europe." The social context within which narcotic trafficking, storage, transportation, and repacking systems exist in Ghana and the state's location along the Gulf of Guinea makes Ghana a more attractive country for the narcotics business. The Narcotics Control Board has impounded container ships at the Sekondi Naval Base in the Takoradi Harbour. These ships were carrying thousands of kilograms of cocaine, with a street value running into billions of Ghana cedis. Drug seizures saw a decline in 2011. Drug cartels are using new methods in narcotics production and narcotics exportation, to avoid Ghanaian security agencies. Underdeveloped institutions, porous open borders, and the existence of established smuggling organisations contribute to Ghana's position in the narcotics industry.
Sources: en.wikipedia.org
Abnormal facial characteristics, consisting of pronounced eyes which are spaced far apart (hypertelorism), a high forehead, a compressed bridge of the nose or saddle nose, and a small lower jaw and chin (micrognathia), are also observed in the majority of cases. Those affected by PD can also suffer intellectual disabilities (approx. 75% of recorded cases do) ranging from mild to severe – mental development during childhood may therefore progress more slowly.
Pseudothrombocytopenia (PTCP) or spurious thrombocytopenia is an in-vitro sampling problem which may mislead the diagnosis towards the more critical condition of thrombocytopenia. The phenomenon may occur when the anticoagulant used while testing the blood sample causes clumping of platelets which mimics a low platelet count. The phenomenon has first been reported in 1969.
On 18 March 2021, German regional leaders including State Premiers and the mayor of Berlin called for the swift approval of the Russian vaccine by the European Medicines Agency to counteract the acute shortages of effective vaccines in Europe. German medical experts have recommended its approval also, and consider the Sputnik Vaccine "clever" and "highly safe". On 19 March 2021, the Philippine Food and Drug Administration granted emergency use authorization for Sputnik V, the fourth COVID-19 vaccine to be given authorization. The Philippine government planned to buy 20 million doses of the vaccine. On 12 April 2021, India approved the use of Sputnik V vaccine for emergency use against COVID-19 based on strong immunogenicity data. As of 12 April 2021, 62 countries had granted Sputnik V emergency use authorization. On 27 April 2021, Bangladesh approved the use of Sputnik V vaccine for emergency use. On 30 April 2021, Turkey and Albania approved the use of Sputnik V vaccine for emergency use.
==== Gene function prediction ==== While genome annotation is primarily based on sequence similarity (and thus homology), other properties of sequences can be used to predict the function of genes. In fact, most gene function prediction methods focus on protein sequences as they are more informative and more feature-rich. For instance, the distribution of hydrophobic amino acids predicts transmembrane segments in proteins. However, protein function prediction can also use external information such as gene (or protein) expression data, protein structure, or protein–protein interactions.
Sources: en.wikipedia.org
RAC/The Sunday Times Taste of Britain Best Restaurant Award 1984 Decanter Magazine Restaurant of the Year 1989 The Good Hotel Guide Cesar Award 1995 Egon Ronay's Guide Restaurant of the Year 1996 Hotel & Restaurant Magazine Seafood Restaurant of the Year 1998, 1999, 2000, 2001 and 2003 The AA Award – English Seafood Restaurant of the Year Award 2002 For the man:
In July 2016, the US EPA released a prepublication version of its final rule on Formaldehyde Emission Standards for Composite Wood Products. These new rules impact manufacturers, importers, distributors, and retailers of products containing composite wood, including fiberboard, particleboard, and various laminated products, who must comply with more stringent record-keeping and labeling requirements.
Ion-exchange resins are widely used in different separation, purification, and decontamination processes. The most common examples are water softening and water purification. In many cases, ion-exchange resins were introduced in such processes as a more flexible alternative to the use of natural or artificial zeolites.
== Portraits == The National Portrait Gallery, London lists 17 portraits of Dorothy Hodgkin including an oil painting of her at her desk by Maggi Hambling and a photograph portrait by David Montgomery. Graham Sutherland made preliminary sketches for a portrait of Dorothy Crowfoot Hodgkin in 1978. One sketch is in the collection of the Science History Institute and another at the Royal Society in London. The portrait was never finished. A portrait of Dorothy Hodgkin by Bryan Organ was commissioned by private subscription to become part of the collection of the Royal Society. Accepted by the president of the society on 25 March 1982, it was the first portrait of a woman Fellow to be included in the Society's collection.
As part of Operation Unified Response, the 2d BCT, on rotation as the division's Global Response Force, was alerted and deployed forces to Haiti later that same day for the mission to provide humanitarian assistance following the devastating earthquake in Haiti. Paratroopers distributed water and food during the 2010 Haiti earthquake relief. Just two months following redeployment from Haiti in 2010, elements of 2d BCT (Red Falcons) deployed to Afghanistan in support of Operation Enduring Freedom to serve as trainers for the Afghan National Security Forces. In October 2011, the Division Headquarters returned to Afghanistan, where they relieved the 10th Mountain Division as the Headquarters of Regional Command-South. In February 2012, 4th BCT deployed to Kandahar province. Taliban commander Mullah Dadullah, formed an overwhelming force in Kandahar. Zhari district in southern Kandahar is where Dadullah was recruiting a high number of jihadists. 4th BCT of the 82nd held the 5-month siege from March 2012 to the end of July, witnessing some of the most intense combat since the initial deployments since 2001, 4th BCT inflicted massive casualties among the Taliban. Performing with an almost perfect strategic plan, 4th BCT drove Dadullah and his men out of Kandahar to the Northeastern province of Kunar, where Dadullah was killed by airstrikes. As of April 2012, the 1st BCT was deployed to Afghanistan, operating in Ghazni Province, Regional Command-East.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.